Evidence map›Paper›PMID 39708822›Full record

ArticleThe Lancet. Infectious diseases2025

Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990-2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021.

GBD 2021 Diarrhoeal Diseases Collaborators

5 registry-linked trialsAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 139 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06839586 phase1 / phase2active not recruitingnot on this map

The Efficacy and Safety of CMTS4520 for Chronic Diarrhoea in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2025 to 2030Enrolled100ConditionsDiarrhoeaArmsCMTS4520 (dietary fiber and probiotics), Placebo
NCT06839599 phase1 / phase2not yet recruitingnot on this map

The Efficacy and Safety of CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults: a Randomized, Double-Blind, Placebo-Controlled Trial.

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2025 to 2030Enrolled100ConditionsDiarrheaArmsCMTS4520 (dietary fiber probiotics), Placebo
NCT07272122 phase3recruitingnot on this mapstarted 2026, after this paper: background citation

Reducing Filth Fly Populations and Transmission of Diarrhoeal Pathogens in Harsh Settings: a Cross-over Trial in South Sudan

TypeinterventionalSponsorThe Mentor InitiativeRan2026 to 2027Enrolled5,556ConditionsDiarrheal DiseasesArmsBaited fly traps - iCatchi® ProMax fly traps, Insect growth regulator (IGR) - effervescent granule containing 2% diflubenzuron (20g/kg)
NCT07758933 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Prospective Study on the Safety of the Postbiotic Lactobacillus LB (Lactéol®) in Immuocompromised Pediatric Patients With Diarrhoeal Disease Treated at the Federico Gómez Children's Hospital of Mexico.

TypeinterventionalSponsorHospital Infantil de Mexico Federico GomezRan2026 to 2026Enrolled30ConditionsDiarrheaArmsLactobacillus LB
NCT07767370 early_phase1recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomised, Controlled, Double-blind Exploratory Study of ND-12 Combined With H-6 in the Treatment of Adult Chronic Inflammatory Diarrhea

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2026 to 2028Enrolled36ConditionsDiarrhea Chronic, UC - Ulcerative ColitisArmsmesalazine, ND-12, ND-12/H-6
3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Human vaccines & immunotherapeutics · 2026
    Review
  7. Review
  8. Bacteriophage Sf14 survival under simulated gastrointestinal conditions.bioRxiv : the preprint server for biology · 2026
    Article
  9. bioRxiv : the preprint server for biology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Acute Diarrheal Disease Associated With Climate Variability and Water Supply System Configuration: An Ecological Study in Brazil.Water environment research : a research publication of the Water Environment Federation · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

GBD 2021 Diarrhoeal Diseases Collaborators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiarrhoeal diseases claim more than 1 million lives annually and are a leading cause of death in children younger than 5 years. Comprehensive global estimates of the diarrhoeal disease burden for specific age groups of children younger than 5 years are scarce, and the burden in children older than 5 years and in adults is also understudied. We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 to assess the burden of, and trends in, diarrhoeal diseases overall and attributable to 13 pathogens, as well as the contributions of associated risk factors, in children and adults in 204 countries and territories from 1990 to 2021.

methodsWe used the Cause of Death Ensemble modelling strategy to analyse vital registration data, verbal autopsy data, mortality surveillance data, and minimally invasive tissue sampling data. We used DisMod-MR (version 2.1), a Bayesian meta-regression tool, to analyse incidence and prevalence data identified via systematic reviews, population-based surveys, and claims and inpatient data. We calculated diarrhoeal disability-adjusted life-years (DALYs) as the sum of years of life lost (YLLs) and years lived with disability (YLDs) for each location, year, and age-sex group. For aetiology estimation, we used a counterfactual approach to quantify population-attributable fractions (PAFs). Additionally, we estimated the diarrhoeal disease burden attributable to the independent effects of risk factors using the comparative risk assessment framework.

findingsIn 2021, diarrhoeal diseases caused an estimated 1·17 million (95% uncertainty interval 0·793-1·62) deaths globally, representing a 60·3% (50·6-69·0) decrease since 1990 (2·93 million [2·31-3·73] deaths). The most pronounced decline was in children younger than 5 years, with a 79·2% (72·4-84·6) decrease in diarrhoeal deaths. Global YLLs also decreased substantially, from 186 million (147-221) in 1990 to 51·4 million (39·9-65·9) in 2021. In 2021, an estimated 59·0 million (47·2-73·2) DALYs were attributable to diarrhoeal diseases globally, with 30·9 million (23·1-42·0) of these affecting children younger than 5 years. Leading risk factors for diarrhoeal DALYs included low birthweight and short gestation in the neonatal age groups, child growth failure in children aged between 1-5 months and 2-4 years, and unsafe water and poor sanitation in older children and adults. We estimated that the removal of all evaluated diarrhoeal risk factors would reduce global DALYs from 59·0 million (47·2-73·2) to 4·99 million (1·99-10·0) among all ages combined. Globally in 2021, rotavirus was the predominant cause of diarrhoeal deaths across all ages, with a PAF of 15·2% (11·4-20·1), followed by norovirus at 10·6% (2·3-17·0) and Cryptosporidium spp at 10·2% (7·03-14·3). In children younger than 5 years, the fatal PAF of rotavirus was 35·2% (28·7-43·0), followed by Shigella spp at 24·0% (15·2-37·9) and adenovirus at 23·8% (14·8-36·3). Other pathogens with a fatal PAF greater than 10% in children younger than 5 years included Cryptosporidium spp, typical enteropathogenicEscherichia coli, and enterotoxigenic E coli producing heat-stable toxin.

interpretationThe substantial decline in the global burden of diarrhoeal diseases since 1990, particularly in children younger than 5 years, supports the effectiveness of health interventions such as oral rehydration therapy, enhanced water, sanitation, and hygiene (WASH) infrastructure, and the introduction and scale-up of rotavirus vaccination. Targeted interventions and preventive measures against key risk factors and pathogens could further reduce this burden. Continued investment in the development and distribution of vaccines for leading pathogens remains crucial.

fundingBill & Melinda Gates Foundation.

Indexed as

DiarrheaGlobal Burden of DiseaseAdolescentAdultAgedChildChild, PreschoolDisability-Adjusted Life YearsFemaleGlobal HealthHumansIncidenceInfantInfant, NewbornMaleMiddle Aged

Identifiers

PMID39708822
PMCPMC12018300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.